Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis

Arch Neurol. 2008 May;65(5):672-4. doi: 10.1001/archneur.65.5.672.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adult
  • Atorvastatin
  • Biomarkers / analysis
  • Biomarkers / blood
  • Central Nervous System / drug effects
  • Central Nervous System / enzymology
  • Central Nervous System / physiopathology
  • Drug Interactions / immunology
  • Drug Therapy, Combination
  • Heptanoic Acids / administration & dosage*
  • Heptanoic Acids / adverse effects
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Interferon beta-1b
  • Interferon-beta / administration & dosage*
  • Matrix Metalloproteinase 9 / blood
  • Matrix Metalloproteinase 9 / drug effects*
  • Multiple Sclerosis, Relapsing-Remitting / blood
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / enzymology*
  • Pyrroles / administration & dosage*
  • Pyrroles / adverse effects
  • Tissue Inhibitor of Metalloproteinase-1 / blood
  • Tissue Inhibitor of Metalloproteinase-1 / drug effects*
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • Biomarkers
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Immunologic Factors
  • Pyrroles
  • Tissue Inhibitor of Metalloproteinase-1
  • Interferon beta-1b
  • Interferon-beta
  • Atorvastatin
  • Matrix Metalloproteinase 9